FGF21 and liver dysplastic nodule: demonstrated that treatment with FGF21 could significantly relieve renal tubulointerstitial lesions and fibrosis by activating the AKT/MDM2/p53 signaling pathway and inhibiting TGF-β/Smad2/3-mediated epithelial-to-mesenchymal transition in the kidneys of mice with DN (97).